Prevalence of colorectal cancer in patients with ulcerative colitis: A retrospective, monocenter study in China

被引:27
作者
Zhang, Qin
Sha, Sumei
Xu, Bin
Liang, Shuhui
Wu, Kaichun
机构
[1] Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Shaanxi Provinc, Peoples R China
[2] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xijing Hosp, Xian 710032, Shaanxi Provinc, Peoples R China
基金
中国国家自然科学基金;
关键词
Colorectal cancer; ulcerative colitis; ulcerative colitis-associated colorectal cancer; INFLAMMATORY-BOWEL-DISEASE; COLON-CANCER; FOLLOW-UP; RISK; METAANALYSIS; CARCINOMA; EPIDEMIOLOGY; COHORT; DIAGNOSIS; DYSPLASIA;
D O I
10.4103/0973-1482.143345
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Ulcerative colitis-associated colorectal cancer (UC-CRC) is a serious complication of UC. Data on the clinical characteristics of patients in China are scarce. Aims: We aimed to study the incidence, characteristics, treatment, and prognosis of CRC patients with a history of UC. Materials and Methods: We identified patients with UC and followed them until the first occurrence of cancer, death, or emigration in a single study center in China. Results: A total of 4 UC-associated CRC patients were identified among the 642 cases recorded from January 2000 to December 2012. The overall risk of cancer was 0.64%. The overall median duration of UC was 15.5 years (range 6-21 years) in patients with UC-associated CRC. Of these patients, 75% (3/4) were at an advanced stage when they were diagnosed. Longer disease duration and extensive colitis were identified as risk factors for developing CRC, and 5-aminosalicylic acid and steroid therapies were not identified as protective factors against UC-associated CRC. Conclusions: Patients with UC are at an increased risk for CRC. However, the prevalence of CRC in China remains lower than that in the West.
引用
收藏
页码:899 / 903
页数:5
相关论文
共 38 条
  • [1] [Anonymous], 2013, International Classification of disease for Oncology
  • [2] Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?
    Bernstein, CN
    Blanchard, JF
    Metge, C
    Yogendran, M
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (12) : 2784 - 2788
  • [3] Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO
  • [4] 2-Z
  • [5] C-KI-RAS MUTATIONS IN CHRONIC ULCERATIVE-COLITIS AND SPORADIC COLON-CARCINOMA
    BURMER, GC
    LEVINE, DS
    KULANDER, BG
    HAGGITT, RC
    RUBIN, CE
    RABINOVITCH, PS
    [J]. GASTROENTEROLOGY, 1990, 99 (02) : 416 - 420
  • [6] Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis
    Castano-Milla, C.
    Chaparro, M.
    Gisbert, J. P.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (07) : 645 - 659
  • [7] Crohn UB, 1925, AM J MED SCI, V170, P220
  • [8] ULCERATIVE COLITIS - EPIDEMIOLOGY AND AETIOLOGY, COURSE AND PROGNOSIS
    DEDOMBAL, FT
    [J]. BRITISH MEDICAL JOURNAL, 1971, 1 (5750) : 649 - &
  • [9] Colorectal cancer prognosis among patients with inflammatory bowel disease
    Delaunoit, T
    Limburg, PJ
    Goldberg, RM
    Lymp, JF
    Loftus, EV
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (03) : 335 - 342
  • [10] Eaden J, 2000, ALIMENT PHARM THERAP, V14, P145